PORTLAND, Ore.--(BUSINESS WIRE)--Nov. 14, 2005--AVI BioPharma, Inc. (Nasdaq:AVII), today announced that it has entered into definitive agreements with several institutional investors for the purchase of 6.9 million shares of its common stock at $3.26 per share in a direct equity placement for gross proceeds to the company of $22.6 million.
